CONTACT FORM

SCIENCE IN ACTION | Raanan Margalit, CEO | +972-52-3400426 | raanan.margalit@gmail.com

3 Pinchas Sapir St., Weizmann Science Park Ness Ziona, ISRAEL

Site Design: Ruth Kenan

 

The Proof of Concept R&D arm of SIA aims to promote the development of newly incepted biopharmaceutical technologies. In addition to offering contract research services, SIA offers partnership in preclinical drug development at early proof of concept stages. For more information and to explore collaboration options, please Contact Us at raanan.margalit@gmail.com or at 972-52-3400426.

PROOF OF CONCEPT R&D
 

Oncology

In recent years we have developed several strategies targeting tumor development and metastatic disease.  

 

One of our approaches is based on developing novel immunotherapeutic “topical” treatment to GI tract disorders with focus on Familial Adenomatous polyposis (FAP) and colon cancer. Preclinical in-vivo studies using APC genetic spontaneous cancer model are completed, showing significant therapeutic effect of the new biological agent. 

 

Another approach comprises gene therapy for tumor growth inhibition by plasmid DNA.

In vitro studies showed encouraging anti-cancerous activity. Currently, we are moving on to in vivo studies in several xenograft tumor models to confirm anti-tumoral activity.

 

In addition, we utilized computational method to develop new peptides counteracting metastatic disease. Administration of leading peptide resulted in marked reduction of metastatic dissemination in mouse non-pulmonary lung metastatic melanoma model.

PROOF OF CONCEPT R&D
PORTFOLIO
Oncology
 

Immunology

Novel leucocytes anti-trafficking agents. Blocking movement of leukocytes out of the circulatory system and towards the site of tissue damage or inflammation, can severely reduce leukocyte accumulation in the tissue. The Pharmacological inhibition of leucocyte trafficking is of great interest for the treatment and prevention of inflammatory/auto-immune diseases such as Multiple Sclerosis, Crohn’s disease, ulcerative colitis, Rheumatoid Arthritis, Host versus graft disease, etc. 

 

Following in-vitro functional assays based on leukocyte transmigration we established and validated lead candidate in in-vivo efficacy studies in animal models for Inflammatory Bowel Disease, Multiple Sclerosis and Autoimmune Hepatitis. We are planning to move forward to clinical trials.

 

Obesity and Fatty Liver Disease

We developed a new strategy to target and reduce white adipose tissue mass and thereby prevent obesity-related medical conditions such as fatty liver. New application to known cellular protein was tested. In in-vivo efficacy studies showed remarkable reduction in weight gain accompanied by significant decrease in liver lipid droplets in high fat diet-induced diabetes and obesity mouse model.